Lewis S. Gruber is CEO, Chief Scientific Officer and Co-Founder of SIWA Therapeutics. He is also the named inventor on all of SIWA Therapeutics’ portfolio of more than 60 global patents.Prior to founding SIWA, Gruber served as interim CEO of ZelleRX, an early stage biotechnology company with a natural killer cell therapy that destroys cancer cells. From 2000 to 2006, Gruber was CEO and Co-Founder of Arryx, Inc., a Chicago biotechnology company that brought to market a breakthrough research tool that uses lasers to allow researchers to simultaneously manipulate hundreds of microscopic objects in three dimensions. Under Gruber’s leadership, Arryx was recognized as a World Economic Forum Technology Pioneer as well as a Red Herring Top 100 Innovator. Before co-founding Arryx, Gruber was CEO of Hyseq, Inc., a biotechnology company with a proprietary genomic platform that facilitated gene discovery and led to the development of numerous therapeutic drugs. While CEO of Hyseq, Gruber completed the largest initial public offering of a biotechnology company in 1997. He also led the negotiation of commercial partnerships that generated more than $100 million.Previously, Gruber was a member of the Illinois Biotechnology Industry Organization (iBio) Board of Directors and served on the Advisory Board of Northwestern University’s Kellogg School of Management Center for Biotechnology. Currently, Gruber serves on the Board of Trustees for the Field Museum of Natural History and is a member of the Advisory Council of the Oriental Institute at the University of Chicago. Before becoming a biotech entrepreneur, Gruber was a patent attorney in Chicago and specialized in the biotechnology, life sciences, pharmaceuticals, genomics and medical device industries. Gruber earned his J.D. from Arizona State University in 1981, an M.S. in Biology from the University of Arizona in 1978 and a Bachelor of Science in Sociology from the University of Arizona in 1973.
Misty Gruber is the Chief Administrative Officer, a Director and a Co-Founder of SIWA Therapeutics. She leads strategic planning and SIWA’s interaction with government regulatory authorities and is responsible for SIWA’s scientific and financial communications to investors and regulators. Prior to co-founding SIWA, Ms. Gruber served as Co-Chair of the biotechnology section of law the Dykema Gossett PLLC law firm, with a focus in corporate governance, mergers and acquisitions and securities law matters, including private and public securities offerings. During her almost thirty years as an attorney, she represented issuers, investors, underwriters and venture capital companies. Ms. Gruber was named a Super Lawyer and was recognized in The Best Lawyers in America during her law practice. In addition, she has been a frequent speaker on topics related to domestic and foreign capital markets and authored numerous articles. She has extensive experience counseling biotechnology and life science companies and helping them raise funds and bring breakthrough technologies to market. She was a Co-founder of Arryx, Inc., which brought to market a breakthrough research tool that uses lasers to allow researchers to manipulate objects in three dimensions. Ms. Gruber was also a Co-Founder and Director of Hyseq, Inc., which developed a proprietary genomic platform. In addition, she was licensed as a CPA in Arizona for several years. Previously, Ms. Gruber served on the Advisory Board of Northwestern University’s Kellogg School of Management Center for Biotechnology. Currently, she is a member of the Advisory Council of the Oriental Institute at the University of Chicago and is a former trustee of, and serves as an adviser to, The Leakey Foundation. She earned a B.S in Biology, an M.S. in Physiology and a J.D. from the University of Arizona.
John O. Peters III is the Chairman of the Board of SIWA. Mr. Peters is a former financial executive with over 30 years of experience in several different industries including technology, manufacturing and government services. Most recently he was a founder, board member and the original chief financial officer of Triple Canopy, Inc., one of the world’s largest private security firms providing high end services to the United States Government and commercial companies operating in high risk environments. Triple Canopy, now Constelis, was successfully sold to a private equity firm in 2015. Mr. Peters is a CPA and has a BBA from Loyola University of Chicago and an MBA from the University of Chicago. He is a member of the AICPA. Mr. Peters works with several charitable institutions. He is a knight of the Holy Sepulcher of Jerusalem and is joining the Visiting Committee of the Oriental Institute at the University of Chicago.
James Alvarez is a member of the Board of SIWA. Prior to joining SIWA, Mr. Alvarez founded Gesture in May of 2011. Over the next 7 years, Gesture would go on to support over 5,500 charity events and helped charity partners raise over $1 billion dollars. Gesture was successfully acquired in November 2017. Prior to Gesture, Mr. Alvarez was the founder of 5 other companies. He has a B.S. from Indiana University.
Alex Kormushoff is a member of the Board of SIWA. Over a 30-year career, Mr. Kormushoff has been at the forefront of important technology trends in the fields of predictive analytics, healthcare technology, and information technology. Most recently, Alex was the President of Strategic Healthcare Programs a company that provides real-time analytics solutions for the healthcare industry. At SHP, Alex was responsible for all aspects of the business and he led the successful exit of SHP in August of 2014. Previously, Alex was the Executive Director of Accenture Analytics where he led the Global Health and Public Service Market. Additionally, he was responsible for all investment activity across Accenture Analytics.
Scientific Advisory Board
John Ford, Ph.D. – Member of SIWA Scientific Advisory Board; Senior Scientific Consultant. Dr. Ford has extensive drug discovery, development, lifecycle management and business development experience from roles at both start-up and global biopharmaceutical companies. He has a proven record of building successful companies, biomedical research and business development. John led drug discovery/development efforts at Hyseq Inc. and Genset SA and was responsible for initiating and/or managing 9 preclinical programs (including discovery of anti-inflammatory cytokines IL- 36 and IL-38). At Takeda Pharmaceuticals, he participated in 4 drug launches, lifecycle management research for 5 marketed drugs and helped to initiate two clinical trials for new oncology indications for a monoclonal antibody drug. In addition, he helped to establish and operate the US portion of a global business development and research sourcing program providing 38 business development leads and supporting 20 internal early-stage research programs. He also assisted in the evaluation of an instrument to fund high-risk internal programs through venture capital investors. Dr. Ford is a Senior Medical Science Liaison at Agios Pharmaceuticals.
Stuart Kupfer, M.D. – Member of SIWA Scientific Advisory Board; Senior Scientific Consultant. Dr. Kupfer is a physician-scientist with extensive leadership experience in clinical and business development strategy and clinical and basic research. He has 19 years of experience in pharmaceutical development of novel agents in multiple therapeutic areas in collaboration with FDA, EMA, and PMDA, leading to numerous global regulatory approvals. Most recently, Dr. Kupfer spent 12 years at Takeda, holding positions of increasing responsibility as Senior Medical Director, Executive Medical Director, and VP Therapeutic Area Head, with accountability for the clinical development portfolio in the cardiovascular and metabolic therapeutic area. Among other experience, he served as Assistant Professor at Washington University in St. Louis leading research programs to investigate immunomodulators of osteoclast function and gene regulation of steroid hormone receptors. Dr. Kupfer has also practiced and taught clinical endocrinology and diabetes in academic hospital settings.
Thomas Tang, PhD. – Member of SIWA Scientific Advisory Board; Dr. Tang, a founder and CEO of First Dimension BioSciences, is an inventor and informatics scientist with over 20 years of experience in genomics and bioinformatics research, as well as product development. He has published over 25 research papers and has procured 90 issued US patents. Dr. Tang has led US scientists in discovering over 20 percent of all human genes. He discovered and named four important gene families, including an insulin-like family of human hormones, a GPCR-like membrane protein family, a family of neural growth factors, and a family of stem cell growth factors. Dr. Tang has an MS in Mathematics, as well as a BS in Biology and Ph.D. in Mathematics, University of Utah.